About Thrixen
Thrixen is a company based in Singapore (Singapore) founded in 2021 by Peter Preiser, Megan Mcbee, Hadley Sikes, Patthara Kongsuphol, Huan Jia, and Shavit N Clein. Thrixen has raised $7 million across 1 funding round from investors including 22Health Ventures and John Ballantyne. Thrixen offers products and services including Diagnostic Platform and Engineered Protein Binders. Thrixen operates in a competitive market with competitors including EKF, ProciseDx, LumiraDx, SpinChip and LightDeck Diagnostics, among others.
- Headquarter Singapore, Singapore
- Founders Peter Preiser, Megan Mcbee, Hadley Sikes, Patthara Kongsuphol, Huan Jia, Shavit N Clein
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Thrixen Pte. Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7 M (USD)
in 1 rounds
-
Latest Funding Round
$7 M (USD), Series A
Apr 29, 2024
-
Investors
22Health Ventures
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Thrixen
Thrixen offers a comprehensive portfolio of products and services, including Diagnostic Platform and Engineered Protein Binders.
Enables rapid biomarker detection using engineered protein binders.
Facilitates affordable and scalable diagnostic solutions for health applications.
Funding Insights of Thrixen
Thrixen has successfully raised a total of $7M through 1 strategic funding round. The most recent funding activity was a Series A round of $7 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Thrixen
Thrixen has secured backing from 2 investors, including venture fund and angel investors. Prominent investors backing the company include 22Health Ventures and John Ballantyne.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage healthtech investments are made by 22Health Ventures.
|
Locked | Locked | Locked | |
|
JB
John Ballantyne |
-
|
Locked | Locked | Locked |
Investor details for Thrixen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Thrixen
Investment portfolio details for Thrixen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Thrixen
Detailed financials for Thrixen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Thrixen Comparisons
Peer comparison for Thrixen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Thrixen
Thrixen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as EKF, ProciseDx, LumiraDx, SpinChip and LightDeck Diagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Point-of-care and laboratory blood analyzers are developed by EKF.
|
|
| Locked | Locked | Locked |
Point-of-care diagnostic devices for immunoassay tests are provided to clinicians.
|
|
| Locked | Locked | Locked |
Cloud based diagnostics platform for point of care diagnosing
|
|
| Locked | Locked | Locked |
In-vitro diagnostic test cartridges are developed and manufactured via R&D.
|
|
| Locked | Locked | Locked |
Point-of-care diagnostic devices for multiplex assays are developed.
|
|
| Locked | Locked | Locked |
Medical diagnostics solutions are researched by the laboratory.
|
Detailed competitors of Thrixen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Thrixen
Complete news archive for Thrixen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Thrixen
Thrixen was founded in 2021 and raised its 1st funding round 3 years after it was founded.
Thrixen is headquartered in Singapore, Singapore.
Shavit N Clein is the current CEO of Thrixen. They have also founded this company.
Thrixen is a funded company, having raised a total of $7M across 1 funding round to date.
Thrixen was founded in 2021 in Singapore as a biotech and medtech company. Diagnostic systems for neutralizing antibody tests, particularly for COVID-19 detection, are researched and developed. Proprietary technology is utilized for biomarker detection, multiplexing, rapid testing, and protein engineering. Operations focus on advancing infectious disease diagnostics through integrated platforms.
Thrixen offers Diagnostic Platform and Engineered Protein Binders.
Thrixen has 2 investors. Key investors include 22Health Ventures, and John Ballantyne.